| Identification | Back Directory | [Name]
LY2140023 hydrochloride | [CAS]
635318-26-2 | [Synonyms]
LY2140023 hydrochloride
Pomaglumetad methionil (hydrochloride) | [Molecular Formula]
C12H19ClN2O7S2 | [MDL Number]
MFCD32878226 | [MOL File]
635318-26-2.mol | [Molecular Weight]
402.871 |
| Hazard Information | Back Directory | [Uses]
Pomaglumetad methionil hydrochloride (LY2140023 hydrochloride) is an orally active, methionine prodrug of the selective mGlu2/3 receptor agonist LY404039. Pomaglumetad methionil hydrochloride has the potential for schizophrenia research[1][2]. | [Biological Activity]
Pomaglumetad methionil hydrochloride (LY2140023 hydrochloride) is an orally active, methionine prodrug of the selective mGlu2/3 receptor agonist LY404039. Pomaglumetad methionil hydrochloride has the potential for schizophrenia research[1][2].
Pomaglumetad methionil (LY2140023) is a high-affinity peptide transporter 1 (PEPT1) substrate with a Km value of ~30 μM[2].LY2140023 is active against [14C]Gly-Sar with an IC50 value of 0.018 mM[2].
Pomaglumetad methionil (LY2140023; orally; 3-300 mg/kg; once daily for 7 days) dose-dependent increases the levels of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) [1]. | [in vivo]
Pomaglumetad methionil (LY2140023; orally; 3-300 mg/kg; once daily for 7 days) dose-dependent increases the levels of the dopamine metabolites dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA) [1]. | Animal Model: | Male Fischer rats (approximately 250 g)[1] | | Dosage: | 3 mg/kg, 10 mg/kg, and 300 mg/kg | | Administration: | Orally; once daily for 7 days | | Result: | Dose-dependent increased the levels of the dopamine metabolites DOPAC and HVA.
|
| [IC 50]
mGluR2; mGluR3 | [References]
[1]. Lowe S, et al. Effects of a novel mGlu?/? receptor agonist prodrug, LY2140023 monohydrate, on central monoamine turnover as determined in human and rat cerebrospinal fluid. Psychopharmacology (Berl). 2012 Feb;219(4):959-70. [2]. Y Anne Pak, et al. In Vitro and Clinical Evaluations of the Drug-Drug Interaction Potential of a Metabotropic Glutamate 2/3 Receptor Agonist Prodrug with Intestinal Peptide Transporter 1. Drug Metab Dispos. 2017 Feb;45(2):137-144. |
|
| Company Name: |
NCE Biomedical Co.,Ltd.
|
| Tel: |
4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988 |
| Website: |
m.is0513.com/ShowSupplierProductsList15748/0.htm |
| Company Name: |
SPIRO PHARMA
|
| Tel: |
|
| Website: |
www.spiropharma.com.cn |
|